The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials

Current Atherosclerosis Reports

Volumn 13, Issue 5, 2011, Pages 422-430

  Hecht, Harvey S ^a  

^a LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Absolute risk; Coronary artery calcium score; Normal cholesterol; Outcomes; Primary prevention statin trials; Relative risk

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ARTICLE; ATHEROSCLEROSIS; CARDIAC IMAGING; CARDIOVASCULAR RISK; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; HUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; REFERENCE VALUE; RISK REDUCTION; SECONDARY PREVENTION; STUDY DESIGN; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CALCINOSIS; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DEMOGRAPHY; DIAGNOSTIC IMAGING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; REFERENCE VALUES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 81055157962     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0194-z     Document Type: Article

References (42)

1. Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary risk factors, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158-65.
2. Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-70. (Pubitemid 46661110)
3. Becker A, Leber A, Becker C, Knez A. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J. 2008;155:154-60. (Pubitemid 350237677)
4. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups.N Engl J Med 2008;358:1336-1345. (Pubitemid 351468410)
5. Erbel R, Möhlenkamp S, Moebus S, et al, for the Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:1397-1406.
6. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: The ARIC (Atherosclerosis Risk In Communities). Study .J Am Coll Cardiol 2010;55:1600-7.
7. Taylor AJ, Cerqueira M, Hodgson JM, et al ACCF/SCCT/ACR/AHA/ASE/ASNC/ SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. J Am Coll Cardiol 2010; 56: 1864-1894.
8. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for assessment of cardiovascular risk in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-103.
9. Friedewald VE, Ballantyne CM, Davidson MH, et al. The Editor's Roundtable: Lipid management beyond statins - Reducing residual cardiovascular risk. Am J Cardiol. 2008;102:559-67.
10. Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757-63.
11. Roberts WC. It's the cholesterol, stupid. Am J Cardiol. 2010;106:1364-6.
12. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation. 2005;112:563-71. (Pubitemid 41060797)
13. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166-72. (Pubitemid 40905146)
14. Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months. A multicenter, randomized, double-blind trial. Circulation. 2006;113:427-37. (Pubitemid 43803205)
15. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004;24:1-7.
16. Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. J Am Coll Cardiol Img 2010;3:1229-1236.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian SimvastatinSurvival Study (4S). Lancet. 1994;344:1383-9.
18. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446-52. (Pubitemid 28191299)
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
20. Ridker PM, Danielson E, Fonseca FAH, et al. For the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
21. Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Caroti Artery Progression Study Research Group. Stroke. 1996;27:480-5. (Pubitemid 26081446)
22. Hecht HS. Naghavi M. Cardiovascular residual risk assessment in patients undergoing therapy: A combined structural and functional approach. Current Cardiovascular Imaging Reports 2009, 2: 405-409.
23. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141:375-82. (Pubitemid 32200265)
24. Wong ND, Budoff MJ, Pio J, Detrano RC. Coronary calcium and cardiovascular event risk: evaluation by age- and sex-specific quartiles. Am Heart J. 2002;143:456-9. (Pubitemid 34185176)
25. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37 month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571-6. (Pubitemid 36628938)
26. Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all cause mortality. Radiology. 2003;228:826-33. (Pubitemid 37025495)
27. Shemesh J, Morag-Koren N, Goldbourt U, et al. Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens. 2004;22:605-10. (Pubitemid 38368495)
28. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210-5. (Pubitemid 38082815)
29. LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162:421-9. (Pubitemid 41191427)
30. Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol. 2005;46:807-14. (Pubitemid 41224803)
31. Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol Img 2009;2:692-700.
32. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Img 2009;2:675-688.
33. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
34. Shepherd J, Cobbe SM, Ford I, et al. For the west od scotland coronary prevention group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:301-7.
35. Colhoun HM, Betteridge DJ, Durrington PN, et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. (Pubitemid 39140624)
36. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in noninsulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478-85. (Pubitemid 44127567)
37. Sever PS, Dahlof B, Poulter NR, et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin inhypertensive patients who have average or lowerthan-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. (Pubitemid 36398384)
38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998-3007.
39. John R, Downs JR, Michael Clearfield M, Weis S, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-22. (Pubitemid 28248586)
40. Nakamura H, Arakawa K, Itakura H, et al. For the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63. (Pubitemid 44444932)
41. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: The Dallas Heart Study. Circulation. 2006;113:38-43. (Pubitemid 43958486)
42. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention. A Meta-analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med. 2010;170:1024-31.